Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Migraine is a common pathology, affecting around 12% of the general population, up to 25% in
some cohorts, as well as a significant part of the reasons for emergency room visits.
Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in
patients with migraine.
However, several aspects of its pathophysiology, still studied to this day, suggest that the
use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia,
cerebrovascular dysfunction with vasodilation, inflammation, etc.
In addition, high-flow oxygen therapy has no significant side effects and almost no
contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of
a migraine attack would thus allow less recourse to conventional analgesics (with significant
side effects for some), a shorter stay in the emergency room, and therefore a benefit in
terms of cost and relief for the patient.
In this context, the sponsor wish to carry out a multicenter prospective interventional,
single-blind randomized placebo-controlled in parallel groups study.